Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
140 mg SC
DRUG
2 trials
Sponsors
Bausch Health Americas, Inc.
Conditions
Psoriasis
Phase 1
Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827
Completed
NCT00867100
Bausch Health Americas, Inc.
Psoriasis
Start: 2007-12-31
End: 2009-09-30
Updated: 2019-01-16
Phase 2
Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis
Completed
NCT00975637
Bausch Health Americas, Inc.
Psoriasis
Start: 2009-12-31
End: 2010-09-30
Updated: 2019-06-26
Related Papers
Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses.
2024-09-12
4 citations
Malignancy Rates in Brodalumab Clinical Studies for Psoriasis
American Journal of Clinical Dermatology
2020-03-23
18 citations
Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
American Journal of Clinical Dermatology
2019-09-09
40 citations
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
2012-03-01
717 citations